Page last updated: 2024-12-07

butyryl-coenzyme a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Butyryl-coenzyme A (butyryl-CoA) is a key intermediate in the metabolism of fatty acids. It is synthesized by the enzyme acyl-CoA synthetase, which catalyzes the reaction between butyrate and coenzyme A. Butyryl-CoA can be further metabolized by beta-oxidation, a process that breaks down fatty acids into acetyl-CoA, which can then be used for energy production in the citric acid cycle. Butyryl-CoA also plays a role in the synthesis of ketone bodies, which are an alternative source of energy for the brain during periods of prolonged fasting or starvation. Butyryl-CoA is an important molecule in the study of metabolism and its role in health and disease. For example, butyryl-CoA is thought to be involved in the pathogenesis of several diseases, including diabetes, cancer, and Alzheimer's disease. The study of butyryl-CoA can provide insights into the mechanisms of these diseases and may lead to the development of new therapies. Butyryl-CoA is also a valuable tool for studying the regulation of fatty acid metabolism and the role of coenzyme A in cellular processes.'
```

Cross-References

ID SourceID
PubMed CID122283
CHEBI ID15517
SCHEMBL ID60439
MeSH IDM0082533

Synonyms (27)

Synonym
CHEBI:15517
4:0-coa
coenzyme a, s-butanoate
butanoyl-coenzyme a
s-butyryl-coenzym-a
s-butyryl-coenzyme a
3'-phosphoadenosine 5'-(3-{(3r)-4-[(3-{[2-(butanoylsulfanyl)ethyl]amino}-3-oxopropyl)amino]-3-hydroxy-2,2-dimethyl-4-oxobutyl} dihydrogen diphosphate)
s-butyryl-coa
s-butanoyl-coa
c4:0-coa
s-butanoyl-coenzyme a
BCO ,
ranosyl]-
9h-purin-6-amine,9-[5-o-[hydroxy[[hydroxy[[(3r)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-[[2-[(1-oxobutyl)thio]ethyl]amino]propyl]amino]butyl]oxy]phosphinyl]oxy]phosphinyl]-3-o-phosphono-beta-d-ribofu
butyryl-coenzyme a
C00136
2140-48-9
s-[2-[3-[[(2r)-4-[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] butanethioate
coenzyme a, butyryl-
SCHEMBL60439
butanoyl coenzyme a
butyryl coa
LMFA07050292
s-{(3s,5s,9r)-1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3lambda~5~,5lambda~5~-diphosphaheptadecan-17-yl} butanethioate (non-pre
DTXSID70943955
butyryl-coa; (acyl-coa); [m+h]+;
butyryl coenzyme a (sodium salt)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
butanoyl-CoAsAny short-chain fatty acyl-CoA in which the acyl group specified is butanoyl or its substituted derivative.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Butanoate metabolism ( Butanoate metabolism )1518
Butanoyl-CoA + Acceptor = Crotonoyl-CoA + Reduced acceptor ( Butanoate metabolism )12
Male infertility03
Mitochondrial beta-oxidation064
Fatty acid beta-oxidation 2011
Fatty acid beta-oxidation025
Metabolism overview078

Research

Studies (96)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (21.88)18.7374
1990's10 (10.42)18.2507
2000's20 (20.83)29.6817
2010's35 (36.46)24.3611
2020's10 (10.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.95 (24.57)
Research Supply Index4.58 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index47.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other95 (97.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]